Key result
Elevated cardiac troponin I levels on admission in patients with acute cerebral infarction treated with thrombolysis were associated with a 1.80-fold increased risk of 5-year mortality.
Why the study?
Plasma cardiac troponin I predicts short-term mortality and is elevated in acute cerebral infarction, but few studies have evaluated its association with long-term mortality following thrombolysis.
Does elevated cardiac troponin I on admission predict long-term mortality in patients with acute cerebral infarction following thrombolysis?
Cohort (n=145)
No
Does elevated cardiac troponin I on admission predict long-term mortality in patients with acute cerebral infarction following thrombolysis?
Elevated cardiac troponin I on admission is an independent predictor of 5-year mortality in patients with acute cerebral infarction treated with intravenous thrombolysis.
Answers are grounded in this paper and cite their sources.
May flag higher 5-year mortality risk after thrombolysis in acute stroke; hypothesis-generating and requires prospective validation.
BACKGROUND/OBJECTIVE: Cardiac diseases are frequently accompanied by elevated levels of biomarkers, among which, troponin is commonly investigated. The levels of plasma cardiac troponin I (cTnI), which has been shown to predict short-term mortality, are elevated in patients with acute cerebral infarction (ACI). However, few studies have assessed the association between cTnI concentration and long-term mortality in patients with ACI following thrombolysis. METHODS: Patients with ACI admitted between January 1, 2014, and December 31, 2016, were registered. Data on demographics and outcomes with elevated cTnI levels were also collected. RESULTS: A total of 145 patients with ACI were recruited; 97 (66%), 30 (20%), and 18 (12%) patients had cTnI concentrations < 0.030 (group 1), 0.030-0.10 (group 2), and > 0.10 μg/L (group 3), respectively. cTnI elevation was associated with older age, atrial fibrillation, congestive heart failure, renal insufficiency, coronary artery disease, stroke severity (National Institutes of Health Stroke Scale score), and prior smoking history at admission. After adjusting for comorbidities and severity at 3 months after ACI, cTnI elevation on admission was significantly associated with ascending 5-year mortality (hazard ratio, 1.80; 95% confidence interval, 1.22-2.65). CONCLUSIONS: Even after adjusting for several possible confounders, cTnI elevation in patients with ACI treated with rt-PA was associated with a 1.80-fold increased risk of 5-year mortality.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2022) conducted a cohort in Acute cerebral infarction (n=145). Elevated cardiac troponin I (cTnI > 0.030 μg/L) vs. Normal cardiac troponin I (cTnI < 0.030 μg/L) was evaluated on 5-year all-cause mortality (HR 1.80, 95% CI 1.22-2.65, p=0.003). Elevated cardiac troponin I levels on admission in patients with acute cerebral infarction treated with thrombolysis were associated with a 1.80-fold increased risk of 5-year mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: